Calix, Inc. filings document the regulatory record of an operating technology company that sells cloud, platform, and managed-service offerings for communications service providers. Its 8-K reports cover quarterly financial results distributed through stockholder letters, including non-GAAP measures such as gross margin, operating expenses, net income, diluted earnings per share, and free cash flow.
Other Calix filings address common-stock repurchase authorizations, board and officer matters, and annual meeting governance. Proxy materials disclose director elections, advisory executive compensation votes, equity and stock purchase plan matters, board oversight, and related stockholder voting items.
Calix, Inc. provides an AI-enabled broadband platform, cloud software and SmartLife managed services that help communication service providers transform into experience-focused “CXPs.” Its Calix One Platform combines access and premises equipment with role-based clouds and an agent workforce to automate subscriber insights and service delivery.
The company serves about 1,600 service providers, mainly in North America, with no customer over 10% of revenue and sales outside the U.S. at 7–9% of revenue in recent years. As of February 9, 2026, 65,607,663 common shares were outstanding and non-affiliate market value was about $2,101 million as of June 27, 2025.
Calix highlights growth opportunities in fiber broadband funding, new managed services and international expansion, but details extensive risks, including dependence on third-party manufacturers and sole- or limited-source suppliers (often in Asia), AI technology and regulatory uncertainty, cybersecurity threats, long sales cycles, intense competition and evolving data-privacy and environmental rules.
Weening Michael reported acquisition or exercise transactions in a Form 4 filing for CALX. The filing lists transactions totaling 217,939 shares at a weighted average price of $45.32 per share. Following the reported transactions, holdings were 16,556 shares.
Durocher John reported acquisition or exercise transactions in a Form 4 filing for CALX. The filing lists transactions totaling 195,439 shares at a weighted average price of $45.32 per share. Following the reported transactions, holdings were 2,367 shares.
Calix Chief Product Officer Shane Eleniak received a grant of stock options covering 195,000 shares of common stock. The options have an exercise price of $39.68 per share.
The award was originally granted on January 31, 2025 as a performance-based option. On February 12, 2026, the Compensation Committee confirmed that the performance criteria for 100% of the grant had been achieved. The option vests 25% on January 31, 2026, with the remaining 75% vesting in equal quarterly installments over 36 months from that date, subject to Eleniak’s continued employment with Calix.
SINDELAR CORY reported acquisition or exercise transactions in a Form 4 filing for CALX. The filing lists transactions totaling 170,439 shares at a weighted average price of $45.32 per share. Following the reported transactions, holdings were 103,994 shares.
Calix director and 10% owner Carl Russo reported indirect stock sales through a trust. On February 3, 2026, The Crescentico Trust, for which Russo serves as trustee, sold 13,477 Calix common shares at a weighted average price of $46.9338 and 11,523 shares at a weighted average price of $47.658, under a pre-established Rule 10b5-1 trading plan adopted on April 25, 2025.
After these transactions, 1,669,188 Calix shares were indirectly held by The Crescentico Trust. Separately, 13,782 shares were indirectly held by Equanimous Investments, an entity whose managing members include Russo and Tim Pasquinelli and for which each individual disclaims beneficial ownership except to the extent of his pecuniary interest. Russo also reported 3,983,070 Calix shares held directly.
Calix, Inc. Chief Financial Officer Cory Sindelar reported exercising stock options and receiving additional common shares. On February 2, 2026, he exercised a stock option for 27,000 shares at an exercise price of $5.05 per share, increasing his direct common stock holdings to 103,555 shares.
The option transaction, reported as a derivative security, left him with 148,000 stock options beneficially owned after the exercise. According to the footnote, all shares subject to this option were fully vested and exercisable as of October 1, 2021.
Calix insider plans to sell 25,000 common shares under Rule 144. The shares are held for the account of a reporting person and are to be sold through Wells Fargo Clearing Services on the NYSE, with an approximate sale date of 02/03/2026 and an aggregate market value of 1,180,432.28.
The 25,000 shares were acquired on 01/30/2023 via stock options from the issuer, paid in cash on the same date. The notice also lists sales during the past three months, including 25,000 shares sold by Crescentico Trust and 395,000 shares sold by Carl Russo, with stated gross proceeds.
Calix, Inc. filed a current report noting it has released a press release and a detailed stockholder letter presenting its financial results for the fourth quarter ended December 31, 2025. Both documents are attached as exhibits.
The stockholder letter highlights several non-GAAP metrics, including non-GAAP gross margin, operating expenses, functional investment categories, effective income tax rate, net income, net income per diluted share and free cash flow. Calix explains these measures exclude non-cash stock-based compensation, intangible asset amortization and certain income tax effects, and are used by management to evaluate performance and set operational goals. Reconciliations to the most comparable U.S. GAAP figures are provided in tabular form in the stockholder letter.
Calix, Inc. expanded its stock repurchase program, which had $109.3 million of remaining authorization as of December 31, 2025. On January 27, 2026, the board approved up to an additional $125 million of buybacks, bringing the total program authorization to $425 million.
The company may repurchase shares from time to time through open market purchases, privately negotiated transactions or other methods, in line with SEC rules and its capital allocation strategy. Calix is not required to repurchase a specific amount of stock and may suspend or discontinue the program at its discretion.